Samuel Wilkinson, MD
Research & Publications
Biography
News
Research Summary
I have research interests in treatment-resistant depression, including ketamine, electroconvulsive therapy (ECT). I have an interest in the potential therapeutic as well as adverse effects of cannabinoids.
Extensive Research Description
1. I have an interest in improving access to and dissemination of preventive measures and evidence-based therapies for depression and other mood disorders. In particular, I am interested in improving the quality and safety of and access to evidenced-based therapies for severe and treatment-resistant depression, which accounts for a disproportionate fraction of the morbidity associated with depression generally. Some of my work thus far relates to the use of electroconvulsive therapy (ECT), which is the most-effective treatment for severe depression. In particular, I have focused on developing and testing relapse prevention strategies that are scalable and would improve the quality and dissemination of these treatments. In this context, I am also interested in partnering with patient stakeholders to design studies that will be of most benefit clinically to patients (patient-centered outcomes research).
2. A promising treatment for severe depression is the intravenous use of sub-anesthetic doses of ketamine. Yet high rates of relapse following treatment precludes broader dissemination of a potentially powerful intervention for patients. My current work examines the potential of cognitive behavioral therapy (CBT) as a relapse prevention strategy following ketamine. This is based on the hypothesis that there is a period of enhanced neuroplasticity following ketamine exposure that may present an opportune time for cognitive and behavioral interventions to harness this enhanced neuroplasticity. The combination of CBT following ketamine may improve longer-term outcomes while at the same time limiting indefinite exposure to ketamine, which is of potential concern. I am also interested in the way that community practitioners and academic sites have adopted ketamine as an off-label treatment for mood disorders and in the development of reasonable practice standards for this emerging treatment which should engender both hope but also caution as it is implemented.
3. Finally, an early research interest was in the rapidly changing legal status of cannabis, including its approval as “medicine” on a state-level despite little evidence examining efficacy or safety in many conditions. One of my works showed that marijuana use was associated with worse outcomes among patients with posttraumatic stress disorder (PTSD), despite the fact that PTSD is an “approved indication” for medical marijuana in many states.
Coauthors
Selected Publications
- Ketamine and the neurobiology of depression: Toward next-generation rapid-acting antidepressant treatmentsKrystal J, Kaye A, Jefferson S, Girgenti M, Wilkinson S, Sanacora G, Esterlis I. Ketamine and the neurobiology of depression: Toward next-generation rapid-acting antidepressant treatments. Proceedings Of The National Academy Of Sciences Of The United States Of America 2023, 120: e2305772120. PMID: 38011560, PMCID: PMC10710048, DOI: 10.1073/pnas.2305772120.
- Psychedelic renaissance: Revitalized potential therapies for psychiatric disordersRhee T, Davoudian P, Sanacora G, Wilkinson S. Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders. Drug Discovery Today 2023, 28: 103818. PMID: 37925136, DOI: 10.1016/j.drudis.2023.103818.
- Cognitive behavioral therapy following esketamine for major depression and suicidal ideation for relapse prevention: The CBT-ENDURE randomized clinical trial study protocolKitay B, Murphy E, Macaluso M, Corlett P, Hershenberg R, Joormann J, Martinez-Kaigi V, Nikayin S, Rhee T, Sanacora G, Shelton R, Thase M, Wilkinson S. Cognitive behavioral therapy following esketamine for major depression and suicidal ideation for relapse prevention: The CBT-ENDURE randomized clinical trial study protocol. Psychiatry Research 2023, 330: 115585. PMID: 37935086, DOI: 10.1016/j.psychres.2023.115585.
- Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 StudyCastro M, Wilkinson S, Al Jurdi R, Petrillo M, Zaki N, Borentain S, Fu D, Turkoz I, Sun L, Brown B, Cabrera P. Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study. CNS Drugs 2023, 37: 715-723. PMID: 37558912, PMCID: PMC10439056, DOI: 10.1007/s40263-023-01026-3.
- Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major DepressionAnand A, Mathew S, Sanacora G, Murrough J, Goes F, Altinay M, Aloysi A, Asghar-Ali A, Barnett B, Chang L, Collins K, Costi S, Iqbal S, Jha M, Krishnan K, Malone D, Nikayin S, Nissen S, Ostroff R, Reti I, Wilkinson S, Wolski K, Hu B. Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression. New England Journal Of Medicine 2023, 388: 2315-2325. PMID: 37224232, DOI: 10.1056/nejmoa2302399.
- Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 studyZaki N, Chen L, Lane R, Doherty T, Drevets W, Morrison R, Sanacora G, Wilkinson S, Popova V, Fu D. Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study. Neuropsychopharmacology 2023, 48: 1225-1233. PMID: 37173512, PMCID: PMC10267177, DOI: 10.1038/s41386-023-01577-5.
- Pharmacological and Somatic Treatment Effects on Suicide in Adults: A Systematic Review and Meta-AnalysisWilkinson S, Diaz D, Rupp Z, Kidambi A, Ramirez K, Flores J, Avila‐Quintero V, Rhee T, Olfson M, Bloch M. Pharmacological and Somatic Treatment Effects on Suicide in Adults: A Systematic Review and Meta-Analysis. FOCUS The Journal Of Lifelong Learning In Psychiatry 2023, 21: 197-208. PMID: 37201149, PMCID: PMC10172559, DOI: 10.1176/appi.focus.23021006.
- Predictors of response and remission in patients with treatment-resistant depression: A post hoc pooled analysis of two acute trials of esketamine nasal sprayTurkoz I, Nelson J, Wilkinson S, Borentain S, Macaluso M, Trivedi M, Williamson D, Sheehan J, Salvadore G, Singh J, Daly E. Predictors of response and remission in patients with treatment-resistant depression: A post hoc pooled analysis of two acute trials of esketamine nasal spray. Psychiatry Research 2023, 323: 115165. PMID: 37019044, DOI: 10.1016/j.psychres.2023.115165.
- Effects of Electroconvulsive Therapy on Functional Outcomes Among Medicare Patients With Comorbid Depression and Dementia: A Nationwide 1-Year Follow-Up Study.Wilkinson S, Sint K, Forester B, Rhee T. Effects of Electroconvulsive Therapy on Functional Outcomes Among Medicare Patients With Comorbid Depression and Dementia: A Nationwide 1-Year Follow-Up Study. The Journal Of Clinical Psychiatry 2023, 84 PMID: 36700843, DOI: 10.4088/jcp.22m14583.
- Efficacy and Safety of Ketamine vs Electroconvulsive Therapy Among Patients With Major Depressive EpisodeRhee TG, Shim SR, Forester BP, Nierenberg AA, McIntyre RS, Papakostas GI, Krystal JH, Sanacora G, Wilkinson ST. Efficacy and Safety of Ketamine vs Electroconvulsive Therapy Among Patients With Major Depressive Episode. JAMA Psychiatry 2022, 79: 1162-1172. PMID: 36260324, PMCID: PMC9582972, DOI: 10.1001/jamapsychiatry.2022.3352.
- Ketamine in the Real World: Where Do We Go From Here?Wilkinson ST. Ketamine in the Real World: Where Do We Go From Here? The Journal Of Clinical Psychiatry 2022, 83 PMID: 36112579, DOI: 10.4088/JCP.22com14648.
- International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderatorsPrice RB, Kissel N, Baumeister A, Rohac R, Woody ML, Ballard ED, Zarate CA, Deakin W, Abdallah CG, Feder A, Charney DS, Grunebaum MF, Mann JJ, Mathew SJ, Gallagher B, McLoughlin DM, Murrough JW, Muthukumaraswamy S, McMillan R, Sumner R, Papakostas G, Fava M, Hock R, Phillips JL, Blier P, Shiroma P, Šóš P, Su TP, Chen MH, Tiger M, Lundberg J, Wilkinson ST, Wallace ML. International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderators. Molecular Psychiatry 2022, 27: 5096-5112. PMID: 36071111, PMCID: PMC9763119, DOI: 10.1038/s41380-022-01757-7.
- At-home ketamine; still a lot to learnWilkinson ST, Sanacora G. At-home ketamine; still a lot to learn. Journal Of Affective Disorders 2022, 318: 150-151. PMID: 36067887, DOI: 10.1016/j.jad.2022.08.090.
- Mental Health Care Resource Utilization and Barriers to Receiving Mental Health Services Among US Adults With a Major Depressive Episode and Suicidal Ideation or Behavior With Intent.Voelker J, Cai Q, Kuvadia H, Daly E, Connolly N, Pesa J, Sheehan J, Wilkinson S. Mental Health Care Resource Utilization and Barriers to Receiving Mental Health Services Among US Adults With a Major Depressive Episode and Suicidal Ideation or Behavior With Intent. The Journal Of Clinical Psychiatry 2021, 82 PMID: 34529898, DOI: 10.4088/jcp.20m13842.
- United States national trends in prevalence of major depressive episode and co-occurring suicidal ideation and treatment resistance among adultsVoelker J, Kuvadia H, Cai Q, Wang K, Daly E, Pesa J, Connolly N, Sheehan J, Wilkinson S. United States national trends in prevalence of major depressive episode and co-occurring suicidal ideation and treatment resistance among adults. Journal Of Affective Disorders Reports 2021, 5: 100172. DOI: 10.1016/j.jadr.2021.100172.
- PMH51 WHAT ARE THE ATTRIBUTES THAT PSYCHIATRISTS CONSIDER IN THE DECISION TO DISCHARGE ADULTS WITH MAJOR DEPRESSIVE DISORDER WHO HAVE BEEN HOSPITALIZED WITH ACTIVE SUICIDAL IDEATION WITH INTENT?Voelker J, Katz E, Nash A, Daly E, Ali A, Lovink A, Stahl J, Desai A, Kuvadia H, Neslusan C, Sheehan J, Wilkinson S. PMH51 WHAT ARE THE ATTRIBUTES THAT PSYCHIATRISTS CONSIDER IN THE DECISION TO DISCHARGE ADULTS WITH MAJOR DEPRESSIVE DISORDER WHO HAVE BEEN HOSPITALIZED WITH ACTIVE SUICIDAL IDEATION WITH INTENT? Value In Health 2020, 23: s210. DOI: 10.1016/j.jval.2020.04.669.
- Ketamine, Esketamine, and A New Generation of AntidepressantsWilkinson S, Kitay B. Ketamine, Esketamine, and A New Generation of Antidepressants. Psychiatric Annals 2020, 50: 54-61. DOI: 10.3928/00485713-20200113-02.
- ASSOCIATIONS OF ADVERSE CHILDHOOD EXPERIENCES WITH DSM-5 DEPRESSIVE DISORDERS AND SUICIDE ATTEMPT IN OLDER ADULTSRhee T, Barry L, Kuchel G, Steffens D, Wilkinson S. ASSOCIATIONS OF ADVERSE CHILDHOOD EXPERIENCES WITH DSM-5 DEPRESSIVE DISORDERS AND SUICIDE ATTEMPT IN OLDER ADULTS. Innovation In Aging 2019, 3: s571-s572. PMCID: PMC6841627, DOI: 10.1093/geroni/igz038.2117.
- S128. Expectancy and Ketamine’s Rapid Antidepressant Effect: A Meta-AnalysisWebler R, Wilkinson S, Kirwin D, Bloch M, Kitay B, Sanacora G. S128. Expectancy and Ketamine’s Rapid Antidepressant Effect: A Meta-Analysis. Biological Psychiatry 2019, 85: s346. DOI: 10.1016/j.biopsych.2019.03.879.
- Interventional psychiatry, a new competency for 21st century psychiatry residentsOstroff R, Kitay B, Wilkinson S, Taylor J. Interventional psychiatry, a new competency for 21st century psychiatry residents. Brain Stimulation 2019, 12: 475. DOI: 10.1016/j.brs.2018.12.547.
- Chapter 35 The Search for Rapid Acting Antidepressants: Research Synthesis and PerspectivesSanacora G, Kitay B, Wilkinson S. Chapter 35 The Search for Rapid Acting Antidepressants: Research Synthesis and Perspectives. 2019, 401-413. DOI: 10.1016/b978-0-12-813333-0.00035-4.
- Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD)Fava M, Freeman MP, Flynn M, Judge H, Hoeppner BB, Cusin C, Ionescu DF, Mathew SJ, Chang LC, Iosifescu DV, Murrough J, Debattista C, Schatzberg AF, Trivedi MH, Jha MK, Sanacora G, Wilkinson ST, Papakostas GI. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Molecular Psychiatry 2018, 25: 1592-1603. PMID: 30283029, PMCID: PMC6447473, DOI: 10.1038/s41380-018-0256-5.
- Leveraging Neuroplasticity to Enhance Adaptive Learning: The Potential for Synergistic Somatic-Behavioral Treatment Combinations to Improve Clinical Outcomes in DepressionWilkinson ST, Holtzheimer PE, Gao S, Kirwin DS, Price RB. Leveraging Neuroplasticity to Enhance Adaptive Learning: The Potential for Synergistic Somatic-Behavioral Treatment Combinations to Improve Clinical Outcomes in Depression. Biological Psychiatry 2018, 85: 454-465. PMID: 30528745, PMCID: PMC6380941, DOI: 10.1016/j.biopsych.2018.09.004.
- Acute and Longer-Term Outcomes Using Ketamine as a Clinical Treatment at the Yale Psychiatric Hospital.Wilkinson ST, Katz RB, Toprak M, Webler R, Ostroff RB, Sanacora G. Acute and Longer-Term Outcomes Using Ketamine as a Clinical Treatment at the Yale Psychiatric Hospital. The Journal Of Clinical Psychiatry 2018, 79 PMID: 30063304, PMCID: PMC6296748, DOI: 10.4088/jcp.17m11731.
- The Successful Use of Electroconvulsive Therapy in a Patient With Cerebral Aneurysms and a Pituitary LesionKitay B, Katz R, Wilkinson S, Ostroff R. The Successful Use of Electroconvulsive Therapy in a Patient With Cerebral Aneurysms and a Pituitary Lesion. Journal Of Ect 2018, 1. DOI: 10.1097/00124509-900000000-99225.
- Erratum to: Ketamine: A Promising Rapid-Acting AntidepressantWilkinson S, Ostroff R, Katz R, Krystal J. Erratum to: Ketamine: A Promising Rapid-Acting Antidepressant. 2018, e1-e1. DOI: 10.1007/978-981-10-6577-4_24.
- S106. Acute and Longer-Term Outcomes Using Ketamine as a Clinical Treatment at the Yale Psychiatric HospitalWilkinson S, Webler R, Katz R, Toprak M, Ostroff R, Sanacora G. S106. Acute and Longer-Term Outcomes Using Ketamine as a Clinical Treatment at the Yale Psychiatric Hospital. Biological Psychiatry 2018, 83: s388. DOI: 10.1016/j.biopsych.2018.02.997.
- Identifying Recipients of Electroconvulsive Therapy: Data From Privately Insured AmericansWilkinson ST, Agbese E, Leslie DL, Rosenheck RA. Identifying Recipients of Electroconvulsive Therapy: Data From Privately Insured Americans. Psychiatric Services 2018, 69: 542-548. PMID: 29385954, PMCID: PMC6248332, DOI: 10.1176/appi.ps.201700364.
- Ketamine: A Promising Rapid-Acting AntidepressantWilkinson S, Ostroff R, Katz R, Krystal J. Ketamine: A Promising Rapid-Acting Antidepressant. 2017, 223-239. DOI: 10.1007/978-981-10-6577-4_16.
- The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-AnalysisWilkinson ST, Ballard ED, Bloch MH, Mathew SJ, Murrough JW, Feder A, Sos P, Wang G, Zarate CA, Sanacora G. The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis. American Journal Of Psychiatry 2017, 175: 150-158. PMID: 28969441, PMCID: PMC5794524, DOI: 10.1176/appi.ajp.2017.17040472.
- Considerations on the Off-Label Use of Ketamine as a Treatment for Mood DisordersWilkinson ST, Sanacora G. Considerations on the Off-Label Use of Ketamine as a Treatment for Mood Disorders. JAMA 2017, 318: 793-794. PMID: 28806440, PMCID: PMC6248331, DOI: 10.1001/jama.2017.10697.
- A Survey of the Clinical, Off-Label Use of Ketamine as a Treatment for Psychiatric DisordersWilkinson ST, Toprak M, Turner MS, Levine SP, Katz RB, Sanacora G. A Survey of the Clinical, Off-Label Use of Ketamine as a Treatment for Psychiatric Disorders. American Journal Of Psychiatry 2017, 174: 695-696. PMID: 28669202, PMCID: PMC5549850, DOI: 10.1176/appi.ajp.2017.17020239.
- Cognitive Behavior Therapy May Sustain Antidepressant Effects of Intravenous Ketamine in Treatment-Resistant DepressionWilkinson ST, Wright D, Fasula MK, Fenton L, Griepp M, Ostroff RB, Sanacora G. Cognitive Behavior Therapy May Sustain Antidepressant Effects of Intravenous Ketamine in Treatment-Resistant Depression. Psychotherapy And Psychosomatics 2017, 86: 162-167. PMID: 28490030, PMCID: PMC5516265, DOI: 10.1159/000457960.
- 201 Measuring Dissociative Effects of NMDA Receptor Antagonists in the Treatment of DepressionSanacora G, Wilkinson S, Van Schalkwyk G. 201 Measuring Dissociative Effects of NMDA Receptor Antagonists in the Treatment of Depression. Biological Psychiatry 2017, 81: s83. DOI: 10.1016/j.biopsych.2017.02.214.
- Computer-Assisted Cognitive Behavior Therapy to Prevent Relapse Following Electroconvulsive TherapyWilkinson ST, Ostroff RB, Sanacora G. Computer-Assisted Cognitive Behavior Therapy to Prevent Relapse Following Electroconvulsive Therapy. Journal Of Ect 2017, 33: 52-57. PMID: 27564424, PMCID: PMC5315599, DOI: 10.1097/yct.0000000000000348.
- Computer-assisted cognitive behavior therapy to prevent relapse following electroconvulsive therapyOstroff R, Wilkinson S, Sanacora G. Computer-assisted cognitive behavior therapy to prevent relapse following electroconvulsive therapy. Brain Stimulation 2017, 10: 524. DOI: 10.1016/j.brs.2017.01.529.
- Hippocampal Volume Changes Following Electroconvulsive Therapy: A Systematic Review and Meta-analysisWilkinson ST, Sanacora G, Bloch MH. Hippocampal Volume Changes Following Electroconvulsive Therapy: A Systematic Review and Meta-analysis. Biological Psychiatry Cognitive Neuroscience And Neuroimaging 2017, 2: 327-335. PMID: 28989984, PMCID: PMC5627663, DOI: 10.1016/j.bpsc.2017.01.011.
- Marijuana use is associated with worse outcomes in symptom severity and violent behavior in patients with posttraumatic stress disorder.Wilkinson ST, Stefanovics E, Rosenheck RA. Marijuana use is associated with worse outcomes in symptom severity and violent behavior in patients with posttraumatic stress disorder. The Journal Of Clinical Psychiatry 2015, 76: 1174-80. PMID: 26455669, PMCID: PMC6258013, DOI: 10.4088/jcp.14m09475.
- Problems With the Medicalization of MarijuanaWilkinson ST, D’Souza D. Problems With the Medicalization of Marijuana. JAMA 2014, 311: 2377-2378. PMID: 24845238, PMCID: PMC6248328, DOI: 10.1001/jama.2014.6175.